At the completion of this activity, the participant will be able to:
1. Examine the proposed mechanisms by which GLP-1 and GLP-1/GIP receptor agonists lower blood pressure.
2. Summarize key clinical trials demonstrating the impact of GLP-1 and GLP-1/GIP receptor agonists on blood pressure reduction.
3. Apply the 2025 JACC Hypertension guideline recommendations to patients with hypertension and type 2 diabetes and/or obesity.
4. Choose appropriate monitoring parameters for patients with hypertension who are taking GLP-1 and GLP-1/GIP receptor agonists.

Session date: 
10/22/2025 - 12:00pm to 1:00pm EDT
Location: 
AGH Kent-Frazier Room (2nd Floor South Tower; Magovern Conference Area) and Zoom Webinar
To Join the Zoom Webinar: https://highmarkhealth.zoom.us/j/98672570454?pwd=VU80YWJYNjgraGVsQ0xkU2xSNWozQT09
Meeting ID: 986 7257 0454; Passcode: 877628
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or register to take this course.